Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT
Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Headache is a common presenting complaint to the emergency department accounting for 1-2% of
patient visits. Of these headaches, approximately 90% are migraine, tension headache, or
combined presentations. The most commonly used migraine therapy in the ED is intravenous
prochlorperazine, but its administration requires close nursing observation, a bed, and the
insertion of an intravenous catheter. Buccal prochlorperazine represents an alternative form
of delivery that enables rapid achievement of therapeutic blood levels and may lead to
symptom resolution. In a randomized, controlled, prospective study,the investigators plan to
assess the efficacy of buccal versus intravenous prochlorperazine for the initial emergency
department treatment of migraine headaches.
Phase:
Phase 3
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center